<DOC>
	<DOCNO>NCT03080415</DOCNO>
	<brief_summary>This open , uncontrolled pilot study thirty chronic HCV infect patient carry Yassin Abdel Ghaffar Charity Center Liver Disease Research . The aim study investigate safety &amp; efficacy combine therapy sofosbuvir ( SOF ) daclatasvir ( DCV ) treat HCV Genotype 4 child age 8 18 . Due previous positive result clinical study drug expect drug high safety high efficacy . Safety measure check adverse effect , efficacy measure Real-Time Quantitative Polymerase Chain Reaction ( qPCR ) detect viral nucleic acid blood sample .</brief_summary>
	<brief_title>Treatment Egyptian Hepatitis C Genotype 4 Infected Children ( Adolescents ) With Combined Sofosbuvir &amp; Daclatasvir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . Age : 818 year 2 . Sex : sexes 3 . Na√Øve patient , chronic HCV infection 1 . Coinfection Hepatitis B virus ( HBV ) 2 . Other associate chronic liver illness 3 . Cirrhotic patient ( indicated biopsy , fibroscan ( F4 ) 4 . Patients history hematemesis ( non cirrhotic portal hypertension ) 5 . Patients drug know interact unfavorably SOF ( Amiodarone , .. )</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>